FDA 483 - Ipca Laboratories Limited - April 26, 2023

This FDA Form 483 details significant quality system and manufacturing deficiencies at a pharmaceutical facility. The firm failed to thoroughly investigate unexplained discrepancies and out-of-specification (OOS) or out-of-trend (OOT) results, specifically citing instances where investigations were incomplete or invalidated without scientific justification. For example, OOS No. SIL/OOS/2022/013 and OOT No. OOT/QC/SIL/015/22 for Assay by HPLC lacked assignable root causes, and the firm proceeded without required manufacturing investigations. The firm also failed to follow validated analytical test methods (Ref. Protocol No. SIL/AMV/SIM/07/00) and established OOS/OOT procedures (CSOP/2017/115, CSOP/2018/155/R09).

A market complaint (MKT/004/2020) regarding spots on tablets was inadequately investigated, with the firm failing to support its proposed root cause and ensure adequate exhaust systems or evaluate HVAC data for room classification. The quality control unit's responsibilities and procedures were not fully followed, leading to untimely, inaccurate, and non-contemporaneously documented deviation investigations and CAPAs. Several CAPAs, such as No. 194953, were not implemented or closed promptly. Repeated human errors in dissolution testing (OOS